Targets › PNP
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2028.
Catalyzes the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate. Preferentially acts on 6-oxopurine nucleosides including inosine and guanosine. (UniProt, P00491)
Open in Phaseline: the race on PNP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roswell Park Cancer Institute | Trifluridine and Tipiracil Hydrochloride Nucleoside analog (thymidine derivative) and thymidine phosphorylase inhibitor; inhibits D | TYMS, PNP | Phase 1 | Advanced Malignant Solid Neoplasm | Sep 2028 |
Advanced Malignant Solid Neoplasm (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.